GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Devices & Instruments » MicroPort CardioFlow Medtech Corp (HKSE:02160) » Definitions » Net-Net Working Capital

MicroPort CardioFlow Medtech (HKSE:02160) Net-Net Working Capital : HK$0.44 (As of Dec. 2023)


View and export this data going back to 2021. Start your Free Trial

What is MicroPort CardioFlow Medtech Net-Net Working Capital?

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full. In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. This is a conservative way of estimating the company's value.

MicroPort CardioFlow Medtech's Net-Net Working Capital for the quarter that ended in Dec. 2023 was HK$0.44.

The industry rank for MicroPort CardioFlow Medtech's Net-Net Working Capital or its related term are showing as below:

HKSE:02160's Price-to-Net-Net-Working-Capital is ranked better than
83.41% of 446 companies
in the Medical Devices & Instruments industry
Industry Median: 6.155 vs HKSE:02160: 1.98

MicroPort CardioFlow Medtech Net-Net Working Capital Historical Data

The historical data trend for MicroPort CardioFlow Medtech's Net-Net Working Capital can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

MicroPort CardioFlow Medtech Net-Net Working Capital Chart

MicroPort CardioFlow Medtech Annual Data
Trend Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Net-Net Working Capital
Get a 7-Day Free Trial -246.27 -0.40 1.04 0.79 0.44

MicroPort CardioFlow Medtech Semi-Annual Data
Dec18 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23
Net-Net Working Capital Get a 7-Day Free Trial Premium Member Only Premium Member Only 1.04 0.89 0.79 0.43 0.44

Competitive Comparison of MicroPort CardioFlow Medtech's Net-Net Working Capital

For the Medical Devices subindustry, MicroPort CardioFlow Medtech's Price-to-Net-Net-Working-Capital, along with its competitors' market caps and Price-to-Net-Net-Working-Capital data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


MicroPort CardioFlow Medtech's Price-to-Net-Net-Working-Capital Distribution in the Medical Devices & Instruments Industry

For the Medical Devices & Instruments industry and Healthcare sector, MicroPort CardioFlow Medtech's Price-to-Net-Net-Working-Capital distribution charts can be found below:

* The bar in red indicates where MicroPort CardioFlow Medtech's Price-to-Net-Net-Working-Capital falls into.



MicroPort CardioFlow Medtech Net-Net Working Capital Calculation

MicroPort CardioFlow Medtech's Net-Net Working Capital (NNWC) per share for the fiscal year that ended in Dec. 2023 is calculated as

Net-Net Working Capital(A: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1164.967+0.75 * 110.468+0.5 * 134.394-264.962
-0-0)/2412.48
=0.44

MicroPort CardioFlow Medtech's Net-Net Working Capital (NNWC) per share for the quarter that ended in Dec. 2023 is calculated as

Net-Net Working Capital(Q: Dec. 2023 )
=(Cash, Cash Equivalents, Marketable Securities+0.75 * Accounts Receivable+0.5 * Total Inventories-Total Liabilities
-Preferred Stock-Minority Interest)/Shares Outstanding (EOP)
=(1164.967+0.75 * 110.468+0.5 * 134.394-264.962
-0-0)/2412.48
=0.44

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In calculating the Net-Net Working Capital (NNWC), Benjamin Graham assumed that a company's accounts receivable is only worth 75% its value, its inventory is only worth 50% of its value, but its liabilities have to be paid in full.

In addition, Graham believed that preferred stock belongs on the liability side of the balance sheet, not as part of capital and surplus. In "Security Analysis", preferred stock is dubbed "an imperfect creditorship position" that is best placed on the balance sheet alongside funded debt.

This is a conservative way of estimating the company's value.


MicroPort CardioFlow Medtech  (HKSE:02160) Net-Net Working Capital Explanation

One research study, covering the years 1970 through 1983 showed that portfolios picked at the beginning of each year, and held for one year, returned 29.4 percent, on average, over the 13-year period, compared to 11.5 percent for the S&P 500 Index. Other studies of Graham's strategy produced similar results.

Benjamin Graham looked for companies whose market values were less than two-thirds of their net-net value. They are collected under our Net-Net screener.


MicroPort CardioFlow Medtech Net-Net Working Capital Related Terms

Thank you for viewing the detailed overview of MicroPort CardioFlow Medtech's Net-Net Working Capital provided by GuruFocus.com. Please click on the following links to see related term pages.


MicroPort CardioFlow Medtech (HKSE:02160) Business Description

Traded in Other Exchanges
Address
No. 1601 Zhangdong Road, Zhangjiang Hi-Tech Park, Pudong New District, Shanghai, CHN, 201203
MicroPort CardioFlow Medtech Corp is a medical device company in China focusing on the research, development, and commercialization of transcatheter and surgical solutions for valvular heart diseases. The company's product portfolio consists of three products VitaFlow, VitaFlow Liberty, and Alwide Plus, and various TAVI products, TMV products, TTV products, surgical valve products, and procedural accessories. Geographically, it derives a majority of its revenue from China.
Executives
China Renaissance Holdings Limited 2201 Interest of corporation controlled by you
Hua Jie Tian Jin Yi Liao Tou Zi He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Shang Hai Hua Hao Qi Ye Guan Li He Huo Qi Ye You Xian He Huo 2101 Beneficial owner
Tian Jin Hua Jie Qi Ye Guan Li Zi Xun He Huo Qi Ye You Xian He Huo 2201 Interest of corporation controlled by you
Tian Jin Hua Qing Qi Ye Guan Li Zi Xun You Xian Gong Si 2201 Interest of corporation controlled by you
Microport Scientific Corporation 2201 Interest of corporation controlled by you
Shanghai Microport Limited 2101 Beneficial owner
China International Capital Corporation Limited 2201 Interest of corporation controlled by you
Cicc Capital Management Co., Ltd. 2201 Interest of corporation controlled by you
Cicc Kangrui I (ningbo) Equity Investment Limited Partners (limited Partnership) 2101 Beneficial owner
Cicc Kangzhi (ningbo) Equity Investment Management Co., Ltd. 2201 Interest of corporation controlled by you

MicroPort CardioFlow Medtech (HKSE:02160) Headlines

No Headlines